AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02644161 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Study NCT02644161 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Least acupuncture stimulation
Description: The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
Study NCT02080507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neuronetics rTMS stimulator
Description: In the active group, magnetic power output will be delivered to the subject through the coils.
Study NCT02080507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Neuronetics rTMS stimulator
Description: In the inactive group, no magnetic power output will be delivered to the subject through the coils.
Study NCT02096588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
Study NCT02096588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/cyclophosphamide
Description: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
Study NCT02096588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide
Description: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
Study NCT02297750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-wire technique in patients undergoing ERCP with biliary cannulation
Study NCT02297750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-wire technique in patients undergoing ERCP with biliary cannulation
Study NCT04257214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
Study NCT01729988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Description: This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.
Study NCT01415050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 15 times WBV
Study NCT03009487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
Study NCT03009487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan 40 mg, Rosuvastatin 20mg
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
Study NCT03009487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
Study NCT02170350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation therapy
Description: Use brief mindful meditation practice
Study NCT02170350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT02170350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT00988208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg lenalidomide orally once each day on Days 1-14
Study NCT00988208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 intravenous docetaxel on Day 1
Study NCT00988208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg prednisone orally twice daily on each day of the treatment cycle
Study NCT00988208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo once each day on Days 1-14 of the treatment cycle
Study NCT04082936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imvotamab
Description: Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
Study NCT02501551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
Study NCT01946035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin XL
Study NCT01946035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00894842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Study NCT00894842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Study NCT01131299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 tablets PO 3 times a day for 12-14 weeks
Study NCT01131299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets PO 3 times a day for 12-14 weeks
Study NCT01131299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha cyclodextrin
Description: 2g PO 3 times a day for 12-14 weeks
Study NCT01605994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid Buffer Predose Solution
Study NCT02279433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS6051b
Description: DS-6051b 50 mg and 200 mg capsules for oral administration
Study NCT01551758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI
Description: FF/VI
Study NCT01551758 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Existing Maintenance Therapy
Description: Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy
Study NCT00189423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)
Description: The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR.
Study NCT03364608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI 90 μg
Description: AS MDI 90 μg (2 actuations of 45 μg/actuation)
Study NCT01131299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha cyclodextrin
Description: 2g PO 3 times a day for 12-14 weeks
Study NCT00189423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (S-CPR)
Description: Conventional standard cardiopulmonary resuscitation (S-CPR)
Study NCT00586157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Study NCT00586157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Study NCT03508869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirvaso® (brimonidine) topical gel, 0.33%
Description: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
Study NCT03508869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport®
Description: Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
Study NCT03508869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Description: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Study NCT00746902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Active nCPAP
Study NCT00062764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos (Pioglitazone)
Description: Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
Study NCT01179230 — intervention group
Intervention type: OTHER
Intervention: SPECT imaging
Description: Dipyridamole stress testing 0.57 mg/kg
Study NCT01179230 — intervention group
Intervention type: OTHER
Intervention: PET imaging
Description: Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
Study NCT01318681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Description: cetirizine 10 mg over encapsulated
Study NCT01318681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: nasal spray 25ug per dose
Study NCT01318681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo nasal spray and placebo capsule are available for double dummy treatment
Study NCT03116126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: 2mg oral daily tablet
Study NCT03116126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive oral daily tablet
Study NCT03901586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction assessment
Description: Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
Study NCT03901586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
Study NCT03901586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gynecological assessment
Description: An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
Study NCT01518413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
Study NCT01518413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
Study NCT04736693 — intervention group
Intervention type: DRUG
Intervention: Raloxifene
Description: Raloxifene dispensing claim is used as the reference group.
Study NCT04736693 — intervention group
Intervention type: DRUG
Intervention: Zoledronic Acid
Description: Zoledronic Acid dispensing claim is used as the exposure group.
Study NCT04312581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: 3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
Study NCT04312581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: physical \& occupational therapy
Study NCT00673504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Sunitinib
Description: Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
Study NCT00673504 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1.000 mg/m2 d1,8,15q4weeks
Study NCT00573833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00573833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00573833 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT02235857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPOSORBER® LA-15 System
Description: LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
Study NCT02799706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
Study NCT02799706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: approved GnRH agonist
Description: A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
Study NCT02799706 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: .As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
Study NCT02799706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: .As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
Study NCT04424303 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Observational study
Study NCT00686023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation (DHS - richard nail)
Description: internal fixation
Study NCT00686023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation (inflatable PFN by DISCOTEC)
Description: internal fixation
Study NCT03364608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS MDI 180 µg
Description: AS MDI 180 μg (2 actuations of 90 μg/actuation)
Study NCT03364608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI (2 actuations)
Study NCT00746902 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: nCPAP
Description: Active nCPAP
Study NCT03364608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil 90 μg
Description: Proventil 90 μg (1 actuation of 90 μg/actuation)
Study NCT03364608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil 180 μg
Description: Proventil 180 μg (2 actuations of 90 μg/actuation)
Study NCT01793051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
Study NCT01793051 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
Study NCT01793051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
Study NCT01793051 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
Study NCT03466489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floraseal
Description: FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
Study NCT03027804 — intervention group
Intervention type: PROCEDURE
Intervention: Ross Operation
Description: Replacement of the aortic valve by means of pulmonary artery autograft
Study NCT03616665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CBASPersonalized
Description: In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented.
Study NCT03535233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT03535233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5 % Topical Spray
Study NCT03535233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate
Study NCT01076634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
Study NCT03284242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treg
Description: Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
Study NCT02731014 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.